Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rhea-AI Summary

Rein Therapeutics (NASDAQ: RNTX) announced the acceptance of their abstract for presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentation will focus on evaluating alveolar regenerative properties of Caveolin Scaffolding Peptides (CSD) in 3D alveolospheres from IPF and normal donor lung samples.

The poster presentation (P1463) is scheduled for Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET, as part of Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.

AUSTIN, Texas, April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.

Details of the poster presentation are as follows:

Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples
Poster #: P1463
Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis
Date & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company's website at reintx.com, or follow them on LinkedIn and X.

Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-announces-abstract-accepted-for-presentation-at-the-american-thoracic-society-2025-international-conference-302439327.html

SOURCE Rein Therapeutics, Inc.

FAQ

What will Rein Therapeutics (RNTX) present at the ATS 2025 Conference?

RNTX will present research on alveolar regenerative properties of Caveolin Scaffolding Peptides in 3D alveolospheres from IPF and normal donor lung samples.

When and where is RNTX's presentation at the ATS 2025 Conference?

The presentation is scheduled for Monday, May 19, 2025, at 11:30 AM PT in San Francisco, CA, as poster #P1463.

What therapeutic areas does Rein Therapeutics (RNTX) focus on?

RNTX focuses on developing first-in-class medicines for orphan pulmonary and fibrosis indications.

Which session will feature RNTX's research at the ATS 2025 Conference?

The research will be presented in Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.